# US 2009/0221689 A1 · Macrocyclic Modulators of the Ghrelin Receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221689 A1
- Document ID: US20090221689A1
- Status: Published application
- Kind: A1
- Application number: 12/351,395
- Filed: 2009-01-09
- Published: 2009-09-03
- Earliest claimed: 2003-06-18
- Assignees: Tranzyme Pharma Inc.
- Inventors: Eric Marsault; Carl St-Louis
- Web page: https://patentgrep.com/patent/US20090221689A1

## CPC

- C07K 5/0827: {containing heteroatoms different from O, S, or N}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 273/00: Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D 498/08: Bridged systems
- C07K 5/0808: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- C07K 5/0812: {and aromatic or cycloaliphatic}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

## Claims

### Claim 1

A pharmaceutically acceptable salt of a macrocyclic compound having the following structure:

### Claim 2 (depends on 1)

The pharmaceutically acceptable salt of claim 1, wherein the salt is an amorphous form.

### Claim 3 (depends on 1)

The pharmaceutically acceptable salt of claim 1, wherein the salt is a crystalline form.

### Claim 4 (depends on 1)

The pharmaceutically acceptable salt of claim 1, wherein the salt is a hydrochloride, hydrobromide or hydroiodide salt.

### Claim 5 (depends on 1)

The pharmaceutically acceptable salt of claim 1, wherein the salt is the hydrochloride salt.

### Claim 6 (depends on 1)

A process for preparing a pharmaceutically acceptable salt of claim 1, the process comprising:
(a) dissolving a macrocyclic compound having the following structure:
in a solution of an alcohol to form solution A;
(b) adding an acid to solution A to form acidified solution A;
(c) optionally cooling acidified solution A; and
(d) separating a precipitated salt from acidified solution A.

### Claim 7 (depends on 6)

The process of claim 6 further comprising:
(a) dissolving the precipitated salt from (d) in a hot mixture of an alcohol and water to form solution C;
(b) cooling solution C; and
(c) separating a precipitated salt from solution C.

### Claim 8 (depends on 6)

The process of claim 6, wherein the alcohol is ethanol.

### Claim 9 (depends on 6)

The process of claim 6, wherein the acid is hydrochloric acid.

### Claim 10 (depends on 6)

The process of claim 6, wherein the precipitated salt is an amorphous form.

### Claim 11 (depends on 6)

The process of claim 6, wherein the precipitated salt is the hydrochloride salt.

### Claim 12 (depends on 7)

The process of claim 7, wherein the alcohol is ethanol.

### Claim 13 (depends on 7)

The process of claim 7, wherein the precipitated salt is a crystalline form.

### Claim 14 (depends on 7)

The process of claim 7, wherein the precipitated salt is the hydrochloride salt.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising:
(a) a pharmaceutically acceptable salt of claim 1; and
(b) a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15 further comprising a growth hormone secretagogue.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the growth hormone secretagogue is hexarelin, GHRP-1, GHRP-2, GHRP-6, ipamorelin, MK-0677, NN7O3, capromorelin, G7039, G7134, G7203, G7502, SM-130686, RC-1291, L-692429, L-692587, L-739943, L-163255, L-163540, L-163833, L-166446, CP-424391, EP-51389, LY-444711, NNC-26-0235, NNC-26-0323, NNC-26-0610, NNC-26-0722, NNC-26-1089, NNC-26-1136, NNC-26-1137, NNC-26-1187, NNC-26-1291, growth hormone releasing factor, IGF-I or IGF-II.
